<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04314206</url>
  </required_header>
  <id_info>
    <org_study_id>VNRX-5024-101</org_study_id>
    <secondary_id>272201600029C-P00007-9999-2</secondary_id>
    <secondary_id>17-0004</secondary_id>
    <nct_id>NCT04314206</nct_id>
  </id_info>
  <brief_title>VNRX-5024 Safety and PK in Healthy Adult Volunteers</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Sequential Group, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single and Repeat Doses of VNRX-5024 Administered Orally for 10 Days in Healthy Adult Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VenatoRx Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>VenatoRx Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2-part dose-ranging study to evaluate the safety and pharmacokinetics of escalating
      doses of VNRX-5024. Subjects will be enrolled in one of three dose cohorts. They will receive
      a single dose on Day 1 in Part 1 and will proceed into the multiple dose Part 2 of the study
      after safety assessments and PK samples are collected. In the multiple dose part of the
      study, subjects will receive multiple doses of VNRX-5024 for 10 days.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Infectious Disease Outbreak: COVID-19
  </why_stopped>
  <start_date type="Actual">February 21, 2020</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>Day 19</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: AUC0-tau</measure>
    <time_frame>Days 1-2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: AUC0-tau</measure>
    <time_frame>Days 3-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Cmax</measure>
    <time_frame>Days 1-2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Cmax</measure>
    <time_frame>Days 3-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: tmax</measure>
    <time_frame>Days 1-2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: tmax</measure>
    <time_frame>Days 3-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: CLr</measure>
    <time_frame>Days 1-2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: CLr</measure>
    <time_frame>Days 3-12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>VNRX-5024</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsule formulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for VNRX-5024</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VNRX-5024</intervention_name>
    <description>Part 1: one dose
Part 2:
Cohort 1: 10 doses (once a day for 10 days) Cohort 2: 19 doses (once every 12 hours [q12h] dosing for 9 days with a single morning dose on Day 10) Cohort 3: 28 doses (once every 8 hours [q8h] dosing for 9 days with a single morning dose on Day 10)</description>
    <arm_group_label>VNRX-5024</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for VNRX-5024</intervention_name>
    <description>Part 1: one dose
Part 2:
Cohort 1: 10 doses (once a day for 10 days) Cohort 2: 19 doses (once every 12 hours [q12h] dosing for 9 days with a single morning dose on Day 10) Cohort 3: 28 doses (once every 8 hours [q8h] dosing for 9 days with a single morning dose on Day 10)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adults 18-55 years

          2. Males or non-pregnant, non-lactating females

          3. Body mass index (BMI): ≥18.5 kg/m2 and ≤32.0 kg/m2

          4. Normal blood pressure

          5. Normal lab tests

        Exclusion Criteria:

          1. Current cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine,
             autoimmune, hematologic, neoplastic, or neurological disorder

          2. History of drug allergy or hypersensitivity to penicillin, cephalosporin, or
             beta-lactam antibacterial drug

          3. Use of antacid medications

          4. Abnormal ECG or history of clinically significant abnormal rhythm disorder

          5. Positive alcohol, drug, or tobacco use/test
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PRA Health Sciences - Early Development Services</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>March 16, 2020</study_first_submitted>
  <study_first_submitted_qc>March 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2020</study_first_posted>
  <last_update_submitted>May 14, 2020</last_update_submitted>
  <last_update_submitted_qc>May 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

